KYMR
Kymera Therapeutics, Inc. (KYMR) Business Model Analysis (2026)
Overall Score
Revenue Model
KYMR has a commercial revenue base, but current valuation remains extremely rich at ~89.1x EV/Sales TTM.
Revenue per share is $1.07 TTM, indicating the business is still early in monetization relative to market value.
Profitability
TTM margins remain deeply negative, with operating margin at -3.34% and net profit margin at -2.85%.
Return metrics are still negative, including ROIC at -22.1% and ROE at -21.5%, showing the business is not yet generating economic profit.
Balance Sheet
Liquidity is very strong, with a current ratio of 9.83x and quick ratio of 9.91x.
Leverage remains low, with debt-to-equity at 0.05x and debt-to-assets at 0.05x, while cash per share is $7.04.
Cash Generation
Cash generation is still negative, with operating cash flow at -$2.41 per share and free cash flow at -$2.42 per share TTM.
Free cash flow yield remains negative at -2.53%, indicating the company is not yet producing positive owner earnings.
Operating Efficiency
Asset turnover is very low at 0.06x, suggesting limited revenue generated from the asset base.
Working capital efficiency remains poor, with a cash conversion cycle of 2,651 days and operating cycle of 1,089 days.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Kymera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

